Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Processed Orange and the Glycemic Response (POGR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02112851
Recruitment Status : Unknown
Verified October 2014 by PepsiCo Global R&D.
Recruitment status was:  Recruiting
First Posted : April 14, 2014
Last Update Posted : October 30, 2014
Sponsor:
Information provided by (Responsible Party):
PepsiCo Global R&D

Brief Summary:
Randomized, placebo controlled, double blind, postprandial crossover study in male subjects. 3 intervention arms, consisting of a control (Product A), a low dose processed whole orange (Product B) and a high dose processed whole orange (Product C), to determine the effect of the interventions on the primary endpoint of postprandial glycemia. Secondarily, plasma insulin concentrations will be quantified.

Condition or disease Intervention/treatment Phase
Maximum Observed Plasma Glucose Concentration (Cmax) Other: Orange flavored beverage Not Applicable

Detailed Description:
The study design is a randomized, placebo controlled, double-blind, crossover. This trial will include 33 subjects randomized to receive products A, B or C [240 mL (255 g)]. Subjects will be randomly assigned to one of 6 sequences of 3 interventions. After the initial screening visit, subjects will visit the Clinical and Translational Research Center (CTRC) the Tufts Translational and Clinical Science Institute (CTSI) on three separate occasions. Following each intervention day there will be a two week wash out period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomized, Placebo-controlled, Double-blind, Crossover Trial to Investigate the Effects of Acute Processed Whole Orange Consumption on Postprandial Glycemic Responses in Healthy Men
Study Start Date : March 2014
Estimated Primary Completion Date : December 2014

Arm Intervention/treatment
Placebo Comparator: Orange flavored beverage
240ml orange beverage
Other: Orange flavored beverage
Intervention involves consumption of one beverage of 240ml following baseline measurements

Experimental: Orange flavored beverage - Test1
240ml processed whole orange low dose
Other: Orange flavored beverage
Intervention involves consumption of one beverage of 240ml following baseline measurements

Experimental: Orange flavored beverage - Test2
240ml processed whole orange high dose
Other: Orange flavored beverage
Intervention involves consumption of one beverage of 240ml following baseline measurements




Primary Outcome Measures :
  1. Maximum observed plasma glucose concentration (Cmax) [ Time Frame: 0-8 hours ]

Secondary Outcome Measures :
  1. Maximum observed plasma insulin concentration (Cmax) [ Time Frame: 0-8 hours ]
  2. Area under the curve (AUC) of glucose and insulin and the time to reach Cmax gluc (Tmax gluc) and Cmax ins (Tmax ins) [ Time Frame: 0-8 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males (due to potential hormonal fluctuations in female subjects) aged 30-65 y
  • BMI: 25-29.9 kg/m2
  • Not diabetic [diagnosed or fasting glucose >7 mmol/L (126 mg/dL)] or suffer from other endocrine disorders
  • Not having suffered a myocardial infarction/stroke in the past 12 mo
  • Not suffering from renal or bowel disease or have a history of choleostatic liver or pancreatitis
  • Not on drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation
  • No history of alcohol misuse
  • Not planning or on a weight reducing regime
  • Not taking any fish oil, fatty acid or vitamin and mineral supplements
  • Non smokers

Exclusion Criteria:

  • Females
  • Use of medications known to affect lipid metabolism, i.e., hypolipidemic or cholesterol-lowering agents (e.g., Pravastatin, Simuvustatin)
  • Use of (>2x/wk) medication for inflammation or hypercoagulation

    • Anticoagulants (Warfarin)
    • Inflammation - NSAID's (Tiaprofenic acid, Sulindac, Ibuprofen), Corticosteroids (Betamethasone)
  • Regular use (>2x/wk) of any acid-lowering medications, laxatives or anti-diarrheal medications (prescription or over-the-counter [OTC])
  • Use of medications known or suspected to influence blood pressure, including beta-adrenergic blocking agents (oral or ocular) (e.g., Sotalol, Bisoprolol), beta-adrenergic drugs, calcium channel blocking agents (Amlodipine, Nicardipine), angiotensin converting enzyme (ACE) inhibitors (Captopril, Cilazapril), angiotensin receptor blocking agents (Valsartan), nitrates, diuretics (Chlortalidone), venlafaxine and sibutramine, decongestants or chloroquine
  • Systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mmHg
  • CVD including coronary artery disease, left ventricular hypertrophy, congestive heart failure, cerebrovascular disease, stroke, peripheral vascular disease or dysautonomia
  • Gastrointestinal diseases conditions or medications influencing gastrointestinal absorption including active peptic ulcer disease, treatment with acid-lowering drugs or inflammatory bowel disease
  • Renal or chronic kidney disease due to any condition, renovascular disease, history of nephrolithiasis or serum creatinine >1.5 mg/dL
  • Endocrine disorders including diabetes [fasting blood glucose >7 mmol/L (126 mg/dL) or current pharmacologic treatment for diabetes], untreated thyroid disease, adrenal disease, pheochromocytoma, parathyroid disease or hyperuricemia
  • Rheumatologic diseases including gout or inflammatory arthritis
  • Active treatment for cancer of any type (except basal cell carcinoma)<1 y
  • Regular use of oral steroids except topical OTC steroids
  • Regular use of any dietary supplements containing vitamins, minerals, herbal or other plant-based preparations, fish oil supplements (including cod liver oil) or homeopathic remedies. However, subjects who are willing to refrain from the use of these supplements for 1 mo prior to their initial visit (Visit 3) may be considered eligible.
  • Usual daily ethanol intake of>2 drinks (24 oz beer, 8 oz wine, 2 oz hard liquor)
  • Cigarette smoking and/or nicotine replacement use. However, subjects who have stopped using these products for 1 y prior to their initial visit (Visit 1) may be considered eligible.
  • Illicit drug use
  • Infrequent (<3/wk) or excessive (>3/d) number of regular bowel movements
  • Specific laboratory blood or urine analysis parameters of:

    • Creatinine > 1.5 mg/dL
    • Electrolytes, calcium, phosphorous - out of normal ranges
    • ALT and AST >1.5 nmol
    • Total bilirubin - above normal range
    • Triglycerides ≥300 mg/dL
    • Fasting glucose ≥126 mg/dL
    • CBC: HCT outside of normal NEL reference ranges at the discretion of the study physician
    • WBC, PLT - outside of normal NEL reference ranges Strict vegetarians
  • Those on or planning a weight reducing regime
  • Unable to consume study meals or products
  • Subjects with larger than 5 kg weight loss in the last 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02112851


Contacts
Layout table for location contacts
Contact: Oliver Chen, PhD 617 556 3128 Oliver.Chen@tufts.edu

Locations
Layout table for location information
United States, Massachusetts
Tufts University Recruiting
Boston, Massachusetts, United States, 02111
Contact: Oliver Chen, PhD    617-556-3128    Oliver.Chen@tufts.edu   
Principal Investigator: Jeffrey Blumberg, PhD         
Sub-Investigator: Oliver Chen, PhD         
Sponsors and Collaborators
PepsiCo Global R&D
Layout table for additonal information
Responsible Party: PepsiCo Global R&D
ClinicalTrials.gov Identifier: NCT02112851    
Other Study ID Numbers: PEP-1326
First Posted: April 14, 2014    Key Record Dates
Last Update Posted: October 30, 2014
Last Verified: October 2014